A Platform of Patient Derived Xenografts (PDX) and 2D/3D Cell Cultures of Soft Tissue Sarcomas (STS)

Launched by THE NETHERLANDS CANCER INSTITUTE · Sep 19, 2016

Keywords

ClinConnect Summary

This clinical trial is investigating new ways to treat soft tissue sarcomas, which are a type of cancer that occurs in the body's connective tissues. The study aims to create a platform using patient-derived xenografts (PDX) and cell cultures to better understand how different treatments, including radiation and targeted therapies, work for various sarcoma subtypes. This approach could help identify more effective treatments tailored to individual patients, improving outcomes and reducing unnecessary side effects.

To participate in this trial, you need to be at least 18 years old and have a confirmed diagnosis of intermediate to high-grade soft tissue sarcoma, which can be newly diagnosed or a local recurrence. You should be willing to undergo biopsies or tumor sampling during surgery. However, if you have certain medical conditions that could complicate the biopsy process or if you have issues that might affect your ability to follow the study's rules, you may not be eligible. If you choose to participate, you can expect to contribute to important research that could lead to better treatments for sarcoma patients in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Histologically confirmed diagnosed (non-) metastatic intermediate to high grade STS
• • Local recurrences are allowed
• • Age ≥ 18 years
• • Able and willing to undergo tumour biopsies or tumour sampling during surgery
• • Localization of sarcoma enables safe biopsy or surgery
• • Written informed consent
• Exclusion Criteria:
• • Known coagulation disorder and/or anticoagulant medication in as far it might interfere with a safe biopsy procedure (to the discretion of the treating physician and attending radiologist)
• • Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the study